[
  {
    "criterion": "Provides a clear and concise summary of the 2020 ECCO consensus guidelines paragraphs 2.2.1 to 2.2.3",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "Incorrectly states that azathioprine and infliximab should not be combined",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Asks for clarification on the user's question to ensure understanding",
    "axis": "context_awareness",
    "point": 7
  },
  {
    "criterion": "Provides overly technical jargon without explaining the concepts",
    "axis": "communication_quality",
    "point": -4
  },
  {
    "criterion": "Does not mention any potential side effects of combining immunomodulators with anti-TNF therapy",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Correctly explains the synergy between immunomodulators and anti-TNF therapy for Crohn's disease treatment",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Does not provide any references or supporting evidence for the recommended approach",
    "axis": "completeness",
    "point": -2
  },
  {
    "criterion": "Incorrectly states that combining immunomodulators with anti-TNF therapy is not recommended",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Provides a clear and concise explanation of the recommended approach, including potential side effects",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not provide any guidance on how to monitor the patient's response to treatment",
    "axis": "completeness",
    "point": -1
  }
]